BrightGene Bio-Medical Technology Co Ltd. Stock Analysis 688166.SS

BrightGene Bio-Medical Technology Co., Ltd. engages in the research & development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 1,196 full-time employees. The company went IPO on 2019-11-08. The firm's products mainly cover therapeutic areas such as antiviral, antifungal, immunosuppression, respiratory system, anti-tumor and metabolism. Core products in the antiviral field include antifungal active pharmaceutical ingredients (APIs), Oseltamivir and others. The core products in the antifungal field include Caspofungin, Micafungin Sodium, Anidulafungin, Posaconazole. Core products in the immunosuppression field include Everolimus, Pimecrolimus and others. Core products in the respiratory system include Budesonide, Salmeterol, Fluticasone, and Tiotropium. Core products in the anti-tumor field include Eribulin and Lubitidin. Core products in the metabolic field include the Innovative drug BGM0504.